(PAHC) Phibro Animal Health - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US71742Q1067

PAHC: Vaccines, Minerals, Antibiotics, Performance Products

Phibro Animal Health Corporation (NASDAQ:PAHC) is a global leader in animal health and mineral nutrition, operating across the U.S., Israel, Brazil, Ireland, and other international markets. The company is structured into three core segments: Animal Health, Mineral Nutrition, and Performance Products. Its diverse product portfolio caters to both food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

The Animal Health segment offers a range of solutions such as antibacterials, anticoccidials, nutritional specialties, and vaccines. These products are designed to enhance animal health, ensure food safety, and improve overall animal welfare. Additionally, Phibro develops and markets microbial and bioproducts for various applications, serving customers in animal health, nutrition, environmental, industrial, and agricultural sectors.

In the Mineral Nutrition segment, the company specializes in trace minerals like zinc, manganese, copper, and iron. These are formulated to meet the dietary needs of livestock, ensuring optimal nutrient balance. Phibro also provides specialty ingredients for personal care, industrial chemicals, and catalyst industries, demonstrating its versatility beyond animal health.

Phibro’s products are distributed through a network of local sales offices, targeting integrated poultry, swine, and cattle producers, as well as commercial animal feed manufacturers, wholesalers, and distributors. The company, originally known as Philipp Brothers Chemicals, Inc., rebranded to Phibro Animal Health Corporation in 2003 and has been operational since 1946, with its headquarters in Teaneck, New Jersey.

Financially, Phibro has a market capitalization of approximately $1.02 billion, with a trailing P/E ratio of 52.48 and a forward P/E of 10.57. The price-to-book ratio stands at 4.04, and the price-to-sales ratio is 0.97. These metrics provide insight into the company’s valuation for investors and fund managers considering its position in the market.

Additional Sources for PAHC Stock

PAHC Stock Overview

Market Cap in USD 958m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2014-04-11

PAHC Stock Ratings

Growth 5y 20.1%
Fundamental -1.13%
Dividend 39.2%
Rel. Strength Industry 78.3
Analysts 2.4/5
Fair Price Momentum 21.89 USD
Fair Price DCF 17.41 USD

PAHC Dividends

Dividend Yield 12m 1.72%
Yield on Cost 5y 2.32%
Annual Growth 5y 0.00%
Payout Consistency 97.1%

PAHC Growth Ratios

Growth Correlation 3m 43.7%
Growth Correlation 12m 84.6%
Growth Correlation 5y -27.2%
CAGR 5y 6.51%
CAGR/Max DD 5y 0.10
Sharpe Ratio 12m -0.08
Alpha 68.26
Beta 1.14
Volatility 42.41%
Current Volume 335.6k
Average Volume 20d 350.6k
What is the price of PAHC stocks?
As of March 15, 2025, the stock is trading at USD 21.25 with a total of 335,608 shares traded.
Over the past week, the price has changed by -10.11%, over one month by -17.13%, over three months by -5.67% and over the past year by +79.87%.
Is Phibro Animal Health a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Phibro Animal Health is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -1.13 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PAHC as of March 2025 is 21.89. This means that PAHC is currently overvalued and has a potential downside of 3.01%.
Is PAHC a buy, sell or hold?
Phibro Animal Health has received a consensus analysts rating of 2.40. Therefor, it is recommend to sell PAHC.
  • Strong Buy: 0
  • Buy: 0
  • Hold: 2
  • Sell: 3
  • Strong Sell: 0
What are the forecast for PAHC stock price target?
According to ValueRays Forecast Model, PAHC Phibro Animal Health will be worth about 23.6 in March 2026. The stock is currently trading at 21.25. This means that the stock has a potential upside of +11.25%.
Issuer Forecast Upside
Wallstreet Target Price 21 -1.2%
Analysts Target Price 19.4 -8.7%
ValueRay Target Price 23.6 11.2%